Russia’s Sputnik V Demonstrates 92% Efficacy Against COVID-19

 Russia’s Sputnik V Demonstrates 92% Efficacy Against COVID-19

Russia’s Sputnik V Demonstrates 92% Efficacy Against COVID-19

Shots:

  • The P-lll study involves assessing of Sputnik V vaccine vs PBO from 19,866 volunteers with COVID-19. The efficacy of the vaccine is 92% effective in fighting COVID-19 based on peer-reviewed late-stage trial results published in the lancet international medical journal
  • Previous data from two-dose regimen of the vaccine based on two different viral vectors administered 21 days apart indicates 91.6% effective against symptomatic COVID-19
  • The findings from Gamaleya Institute in Moscow that developed and tested the vaccine with efficacy data reported at earlier stages of the trial running in Moscow since Sept’2020

Click here ­to­ read full press release/ article | Ref: Reuters | Image: Dawn

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post